Primaris REIT Announces Financial Results Release Date, Webcast, and Conference Call

TORONTO--(BUSINESS WIRE)-- Primaris Real Estate Investment Trust (“Primaris” or the “Trust”) (TSX: PMZ.UN) will be releasing its financial results for the quarter and year ended December 31, 2024, on Thursday, February 13, 2025, after the market closes. Senior leadership will be hosting a conference call and webcast presentation on February 14, 2025.

Conference Call and Webcast:

The call will be accessible for replay until February 21, 2025, by dialing 1-866-813-9403 with access code 171785, or on the Investor Relations section of the website.

About Primaris Real Estate Investment Trust

Primaris is Canada’s only enclosed shopping centre focused REIT, with ownership interests primarily in leading enclosed shopping centres located in growing mid-sized markets. The portfolio totals 13.4 million square feet valued at approximately $4.1 billion at Primaris’ share. Economies of scale are achieved through its fully internal, vertically integrated, full-service national management platform. Primaris is very well-capitalized and is exceptionally well positioned to take advantage of market opportunities at an extraordinary moment in the evolution of the Canadian retail property landscape.

For more information: TSX: PMZ.UN www.primarisreit.com www.sedarplus.ca

View source version on businesswire.com: https://www.businesswire.com/news/home/20250116677798/en/

Alex Avery
Chief Executive Officer
416-642-7837
[email protected]

Rags Davloor
Chief Financial Officer
416-645-3716
[email protected]

Claire Mahaney
VP, Investor Relations & ESG
647-949-3093
[email protected]

Timothy Pire
Chair of the Board
[email protected]

Source: Primaris Real Estate Investment Trust

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Ca
• Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition